MAZE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

6 Analyst Rating

Wall Street analysts forecast MAZE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MAZE is 40.83 USD with a low forecast of 34.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 39.710

Low

34.00

Averages

40.83

High

50.00

Current: 39.710

Low

34.00

Averages

40.83

High

50.00

Wells Fargo

initiated

$55

2025-12-04

Reason

Wells Fargo

Price Target

$55

2025-12-04

initiated

Reason

Wells Fargo initiated coverage of Maze Therapeutics with an Overweight rating and $55 price target. The firm cites the company's "underappreciated potential" in broad APOL1-mediated kidney disease and a backdrop of rising interest in rare kidney assets for the buy rating. Maze's multiple internal and external catalysts in 2026 could de-risk its $3B peak sales opportunity in the U.S., the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

$50 -> $60

2025-12-03

Reason

H.C. Wainwright

Price Target

$50 -> $60

2025-12-03

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Maze Therapeutics to $60 from $50 and keeps a Buy rating on the shares. The firm believes MZE829 is a "best-in-class" APOL1 inhibitor. It cites a key opinion leader discussion and its understanding of the APOL1-mediated kidney disease market for the target boost.

Raymond James

initiated

$48

2025-11-13

Reason

Raymond James

Price Target

$48

2025-11-13

initiated

Reason

Raymond James initiated coverage of Maze Therapeutics with a Strong Buy rating and $48 price target. Maze's lead wholly-owned assets - MZE829 in Phase 2 study for APOL1-mediated kidney disease and MZE782 entering Phase 2 in phenylketonuria and CKD - target high unmet need chronic kidney disease populations and have "best-in-class potential," the analyst tells investors.

Guggenheim

Debjit Chattopadhyay

Buy

maintain

$19 -> $34

2025-09-15

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

$19 -> $34

2025-09-15

maintain

Buy

Reason

Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on Maze Therapeutics to $34 from $19 and keeps a Buy rating on the shares after the company announced clinical results from the Phase 1 healthy volunteer study of MZE782. The healthy volunteer urinary Phe data exceeded a 10-times threshold with the reported 24-55-times increase, indicating a potentially superior profile relative to comps, and the MZ782 data imply the medicine has the potential to beat on efficacy, the analyst tells investors.

H.C. Wainwright

NULL -> Buy

maintain

$34 -> $50

2025-09-12

Reason

H.C. Wainwright

Price Target

$34 -> $50

2025-09-12

maintain

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Maze Therapeutics to $50 from $34 and keeps a Buy rating on the shares. The company's Phase 1 HV data from the MZE782 showed a robust pharmacodynamics signal, far exceeding JNT-517's benchmark, the analyst tells investors in a research note. The firm sees "best-in-class potential" for MZE782 in phenylketonuria.

Leerink

Joseph Schwartz

Outperform

maintain

$28 -> $34

2025-09-11

Reason

Leerink

Joseph Schwartz

Price Target

$28 -> $34

2025-09-11

maintain

Outperform

Reason

Leerink analyst Joseph Schwartz raised the firm's price target on Maze Therapeutics to $34 from $28 and keeps an Outperform rating on the shares. First-in-human Phase 1 data with MZE782 exceeded the firm's expectations and support the potential for a best-in-class profile, the analyst tells investors in a research note. The firm added that it remains positive on the stock ahead of the APOL1 data in early 2026, and that its price target has risen after the firm raised its probability-of-success estimate for MZE782.

Valuation Metrics

The current forward P/E ratio for Maze Therapeutics Inc (MAZE.O) is -12.78, compared to its 5-year average forward P/E of -5.46. For a more detailed relative valuation and DCF analysis to assess Maze Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.46

Current PE

-12.78

Overvalued PE

-1.89

Undervalued PE

-9.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.15

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-1.86

Undervalued EV/EBITDA

-8.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

320.22

Current PS

0.00

Overvalued PS

781.73

Undervalued PS

-141.29

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MAZE News & Events

Events Timeline

No data

News

4.0

12-04NASDAQ.COM

MAZE Surpasses Average Analyst Expectations

4.0

11-08NASDAQ.COM

Wedbush Reaffirms Outperform Rating for Maze Therapeutics (MAZE)

2.0

10-31NASDAQ.COM

Biotech Stocks Reach 52-Week Peaks: MTSR, INSM, ABVX, and MAZE Drive Surge on October 30

People Also Watch

Frequently Asked Questions

What is Maze Therapeutics Inc (MAZE) stock price today?

The current price of MAZE is 39.71 USD — it has increased 2.19 % in the last trading day.

What is Maze Therapeutics Inc (MAZE)'s business?

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

What is the price predicton of MAZE Stock?

What is Maze Therapeutics Inc (MAZE)'s revenue for the last quarter?

Maze Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Maze Therapeutics Inc (MAZE)'s earnings per share (EPS) for the last quarter?

Maze Therapeutics Inc. EPS for the last quarter amounts to -0.66 USD, increased 1000.00 % YoY.

What changes have occurred in the market's expectations for Maze Therapeutics Inc (MAZE)'s fundamentals?

The market is revising No Change the revenue expectations for Maze Therapeutics, Inc. (MAZE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 69.27%.

How many employees does Maze Therapeutics Inc (MAZE). have?

Maze Therapeutics Inc (MAZE) has 125 emplpoyees as of December 16 2025.

What is Maze Therapeutics Inc (MAZE) market cap?

Today MAZE has the market capitalization of 1.91B USD.